scholarly journals Drug susceptibility testing of clinical isolates of streptococci and enterococci by the Phoenix automated microbiology system

2007 ◽  
Vol 7 (1) ◽  
pp. 46 ◽  
Author(s):  
Gioconda R Brigante ◽  
Francesco A Luzzaro ◽  
Beatrice Pini ◽  
Gianluigi Lombardi ◽  
Gertrude Sokeng ◽  
...  
Keyword(s):  
Susceptibility Testing ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
Clinical Isolates ◽  
The Phoenix

scholarly journals Lack of Correlation between embB Mutation and Ethambutol MIC in Mycobacterium tuberculosis Clinical Isolates from China

2007 ◽  
Vol 51 (12) ◽  
pp. 4515-4517 ◽  
Author(s):  
Ruiru Shi ◽  
Jianyuan Zhang ◽  
Koji Otomo ◽  
Guolong Zhang ◽  
Isamu Sugawara
Keyword(s):  
Drug Resistance ◽  
Mycobacterium Tuberculosis ◽  
Susceptibility Testing ◽  
Multiple Drug Resistance ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
Clinical Isolates ◽  
Multiple Drug

ABSTRACT Seventy-four Mycobacterium tuberculosis clinical isolates from China were subjected to drug susceptibility testing using ethambutol, isoniazid, rifampin, and ofloxacin. The results revealed that the presence of embB mutations did not correlate with ethambutol resistance but was associated with multiple-drug resistance, especially resistance to both ethambutol and rifampin.

A novel agar base medium for drug susceptibility testing of Mycobacterium tuberculosis isolates

2021 ◽  
Author(s):  
Ahmet Yilmaz Coban
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Positive Predictive Value ◽  
Negative Predictive Value ◽  
Predictive Value ◽  
Susceptibility Testing ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
Clinical Isolates ◽  
First Line ◽  
Multicenter Studies

Aim: In this study, it was aimed to evaluate AYC.2.2 agar for susceptibility testing of Mycobacterium tuberculosis clinical isolates against first line drugs. Materials & methods: In the present study, 208 M. tuberculosis clinical isolates were tested on AYC.2.2 agar, which was previously validated for the first line drugs isoniazid, rifampicin, streptomycin and ethambutol. Results: Specificity, sensitivity, positive predictive value, negative predictive value and agreement for isoniazid–rifampicin–ethambutol–streptomycin were 100–100–97.2–99.3%, 94.8–94.8–79.3–94.3%, 100–100–82.1–98.03%, 97.03–98.03–96.7–98.08%, 98.07–98.5–94.7-98.07%, respectively. Conclusion: Results had shown that the newly developed AYC.2.2 agar promises as an alternative medium that can be used to perform susceptibility testing of M. tuberculosis isolates. However, further multicenter studies are needed to be used in routine mycobacteriology laboratories.

Drug susceptibility testing of Mycobacterium simiae: An emerging pathogen in Iran

2020 ◽  
Vol 20 ◽  
Author(s):  
Mohammad Javad Nasiri ◽  
Sirus Amini ◽  
Zahra Nikpor ◽  
Samaneh Arefzadeh ◽  
Seyyed Mohammad Javad Mousav ◽  
...  
Keyword(s):  
Drug Testing ◽  
Susceptibility Testing ◽  
Drug Susceptibility ◽  
Multidrug Resistant ◽  
Drug Susceptibility Testing ◽  
Clinical Isolates ◽  
Emerging Pathogen ◽  
Treatment Regimens ◽  
Appropriate Treatment ◽  
Susceptibility Patterns

Introduction: Mycobacterium simiaeis an emerging pathogen in Iran and little is known about drug susceptibility patterns of this pathogen. Materials and methods: Twenty-five clinical isolates of M. simiaefrom 80 patients with confirmed NTM pulmonary disease were included in this study. For drug susceptibility testing (DST), proportional and broth microdilution methods were used according to the clinical and laboratory standards institute (CLSI) guideline. Results: All clinical isolates of M. simiaewere resistant to isoniazid, rifampicin, ethambutol, streptomycin, amikacin, kanamycin, ciprofloxacin, and clarithromycin. They also were highly resistant to ofloxacin (80%). Susceptibility to ofloxacin was only noted in the 5 isolates. Conclusions: Clinical isolates of M. simiae were multidrug-resistant, and had different drug susceptibility patterns than previously published studies. DST results can assist in selecting more appropriate treatment regimens. Newer drugs with proven clinical efficacy correlating with in vitrosusceptibility should be substituted with first-and second-line anti-TB drug testing.

scholarly journals Evaluation of the MGIT 960/EpiCenter TB eXiST system for drug susceptibility testing for Mycobacterium abscessus complex

2021 ◽  
Author(s):  
Natalia de CARVALHO ◽  
Sylvia LEÃO ◽  
Sidney Bombarda ◽  
Robert D Arbeit ◽  
Erica CHIMARA
Keyword(s):  
Internal Control ◽  
Susceptibility Testing ◽  
Collaborative Study ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
Mycobacterium Abscessus ◽  
Clinical Isolates ◽  
Initial Assessment ◽  
Inducible Resistance ◽  
Technical Factors

Abstract Background: Drug susceptibility testing (DST) of the Mycobacterium abscessus complex (MABSC) and other rapidly growing nontuberculous mycobacteria by conventional broth microdilution (BMD) is complicated due to inducible resistance to clarithromycin and other technical factors. The goals of this study were to develop a protocol for performing DST of MABSC clinical isolates on the BACTEC MGIT 960/Epicenter TB eXiST and provide an initial assessment of its reliability and utility.Methods: M. abscessus ATCC19977 was used as the reference strain for developing the protocol and as the internal control for DST done by BMD method per CLSI guidelines plus resazurin. Both methods were applied to 31 MABSC clinical isolates submitted to our reference center. Genotyping was performed for the rrl and erm(41) genes known to impact clarithromycin resistance phenotype.Results: The 31 MABSC isolates included 14 M. abscessus subsp. abscessus, 8 M. abscessus subsp. massiliense, and 9 M. abscessus subsp. bolletii. By standard BMD method, a high percentage of the isolates were resistant to cefoxitin (93.5%) and imipenem (100%), and sensitive to amikacin (96.7%). Comparing microplate and MGIT 960 results across those 93 pairs of results (31 isolates x 3 antibiotics), 75 (80.6%) were concordant and the remaining 18 (19.4%) represented minor errors; there were no major or very major errors. Concordance was 100% for amikacin, 84% for imipenem, and 58% for cefoxitin. Clarithromycin DST by microplate and MGIT 960 both identified 14 (45.2%) isolates as susceptible. Microplate identified 3 (9.6%) isolates as resistant after 3 days incubation, with 14 (45.2%) demonstrating inducible resistance from Day 5 to 14. Among those 17 isolates, the MGIT 960 protocol, without modifications, reported 9 (29.0%) as resistant and 8 (25.8%) as intermediate. For all isolates, the observed clarithromycin susceptibility phenotypes were consistent with the genotypes. Conclusion: This study details the development of a DST protocol for MABSC isolates using the MGIT 960/Epicenter TB eXiST system. Based on direct comparison with the standard BMD, the protocol provided highly reliable results, including, without further modification, detection of isolates with inducible-resistance to clarithromycin. These findings support proceeding to the multi-laboratory collaborative study required for validation of the protocol.

Sign in / Sign up

Export Citation Format

Share Document